10x Genomics, Inc.
NASDAQ: TXG. Canonical company identity and public leadership record.
US
- Alpha ID
- alpha:company:eea287cc-d248-41d5-8b2c-05988aa8b321
- SEC CIK
- 0001770787
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 15, 2026
- Newest evidence
- Apr 24, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Serge SaxonovChief Executive Officer
- Chair
- John R. Stuelpnagel, D.V.M.
- Independent
- Not published9 directors published
- Published claims
- 182 distinct sources
- Evidence records
- 30 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 3 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Adam S. Taich seat on 10x Genomics, Inc., effective 2026-04-24.
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Financial Officer | Adam S. Taich | Apr 2026 | current | Source reportedE3 |
| President and Chief Scientific Officer | Benjamin J. Hindson | Apr 2026 | current | Source reportedE3 |
| Chief Legal Officer | Eric S. Whitaker | Apr 2026 | current | Source reportedE3 |
| Chief Executive Officer | Serge Saxonov | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence9 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Adam S. Taich | Independence not published | 2026 | None published | Source reportedE3 |
| Alan Mateo | Independence not published | 2024 | None published | Source reportedE3 |
| Benjamin J. Hindson | Independence not published | 2012 | None published | Source reportedE3 |
| John R. Stuelpnagel | Independence not published | 2013 | None published | Source reportedE3 |
| Kimberly J. Popovits | Independence not published | 2020 | None published | Source reportedE3 |
| Sarah Teichmann | Independence not published | 2024 | None published | Source reportedE3 |
| Serge Saxonov | Independence not published | 2012 | None published | Source reportedE3 |
| Shehnaaz Suliman | Independence not published | 2019 | None published | Source reportedE3 |
| Sri Kosaraju | Independence not published | 2019 | None published | Source reportedE3 |
| John R. Stuelpnagel, D.V.M. | IndependentChair | Not published | None published | Source reportedE2 |
Committees and risk ownership
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Financials and market context
EvidenceGovernance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- CommitteesNot reviewed. Committee mandates show where oversight is delegated.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Adam S. TaichChief Financial Officer; Directorcompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:15, company:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:6
- Benjamin J. HindsonPresident and Chief Scientific Officer; Directorcompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:16, company:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:8
- Eric S. WhitakerChief Legal Officercompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:17
- Serge SaxonovChief Executive Officer; Directorcompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:18, company:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:12
- Alan MateoDirectorcompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:7
- John R. StuelpnagelDirectorcompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:9
- Kimberly J. PopovitsDirectorcompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:10
- Sarah TeichmannDirectorcompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:11
- Shehnaaz SulimanDirectorcompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:13
- Sri KosarajuDirectorcompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:14
- John R. Stuelpnagel, D.V.M.Chairman of the Board of Directorscompany:eea287cc-d248-41d5-8b2c-05988aa8b321:leadership_role:5
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 3 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 15, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Apr 24, 2026. Retrieved Sep 14, 2026. Cited by 2 Claims.
- E3sec proxy. Published Apr 24, 2026. Retrieved Sep 2, 2026. Cited by 12 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 15, 2026- Adam S. Taich seat on 10x Genomics, Inc., effective 2026-04-24.
- Adam S. Taich executive of 10x Genomics, Inc., effective 2026-04-24.
- Benjamin J. Hindson executive of 10x Genomics, Inc., effective 2026-04-24.
- Eric S. Whitaker executive of 10x Genomics, Inc., effective 2026-04-24.
- Alan Mateo seat on 10x Genomics, Inc., effective 2024-01-01.
- Sarah Teichmann seat on 10x Genomics, Inc., effective 2024-01-01.
- Kimberly J. Popovits seat on 10x Genomics, Inc., effective 2020-01-01.
- Shehnaaz Suliman seat on 10x Genomics, Inc., effective 2019-01-01.
- Sri Kosaraju seat on 10x Genomics, Inc., effective 2019-01-01.
- John R. Stuelpnagel seat on 10x Genomics, Inc., effective 2013-01-01.
- Benjamin J. Hindson seat on 10x Genomics, Inc., effective 2012-01-01.
- Serge Saxonov seat on 10x Genomics, Inc., effective 2012-01-01.



